Intranasal Surface-Modified Mosapride Citrate-Loaded Nanostructured Lipid Carriers (MOS-SMNLCs) for Treatment of Reflux Diseases: In vitro Optimization, Pharmacodynamics, and Pharmacokinetic Studies
- 46 Downloads
Gastroesophageal reflux disease (GERD) is an esophageal injury occurred when the stomach contents reflux abnormally into the esophagus. GERD complications include esophageal adenocarcinoma. Mosapride (MOS) is a safe prokinetic agent potentially used to treat GERD. Yet, its low solubility and bioavailability due to extensive first-pass metabolism limits its applications. This study aimed to formulate MOS nanostructured lipid carriers (MOS-NLCs) via the intranasal route to improve its bioavailability. Melt–emulsification low temperature–solidification technique using 23 full factorial design was adopted to formulate MOS-NLCs. Eight formulae were prepared and assessed in terms of entrapment efficiency (%EE), particle size, and in vitro release. Glycerol addition significantly reduced the particle sizes and improved %EE and %drug released. Surface modification using chitosan was applied. The optimized MOS surface-modified nanostructured lipid carriers (MOS-SMNLCs-F7)(stearic acid, 4% glycerol, 0.5% LuterolF127, 0.5% chitosan) showed low particle size 413.8 nm ± 11.46 nm and high %EE 90.19% ± 0.06% and a threefold increase in permeation of MOS with respect to the drug suspension. MOS-SMNLCs (F7) was also evaluated for its bioavailability compared with drug suspension and commercial product. Statistical analysis revealed a significant increase in gastric emptying rate to be 21.54 ± 1.88 contractions/min compared with10.02 ± 0.62 contractions/min and 8.9 ± 0.72 contractions/min for drug suspension and oral marketed product respectively. Pharmacokinetic studies showed 2.44-fold rise in bioavailability as compared to MOS suspension and 4.54-fold as compared to the oral marketed product. In vitro/in vivo studies proven to level A correlation between in vitro permeation through sheep nasal mucosa and in vivo absorption. Therefore, MOS-SMNLCs could be considered a step forward towards enhancing the clinical efficacy of Mosapride.
KEY WORDSMosapride citrate surface-modified nanostructured lipid carriers intranasal administration in vitro permeation gastric emptying rate
This work was supported by National Organization for Drug Control and Research, Egypt, and Faculty of Pharmacy, Cairo University, Egypt. The ultrasonography examination was conducted with the help of Dr. Mohamed El-said Associate lecturer, Department of Medicine and Infectious Diseases, Faculty of Veterinary Medicine, Cairo University.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
The authors only are responsible for the content and writing of the article.
- 2.Ali AA, Sayed OM. Preparation and characterization of mosapride citrate inclusion complexes with natural and synthetic cyclodextrins. Pharm Dev Technol. 2013;18(5):1–9.Google Scholar
- 3.Fry LC, Mönkemüller K, Malfertheiner P. Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions—a debate: Con. Curr Treat Options Gastroenterol Curr Med Gr LLC ISSN [Internet]. 2007 [cited 2018 Feb 24];10:305–11. Available from: https://link.springer.com/content/pdf/10.1007%2Fs11938-007-0073-4.pdf
- 5.ElMeshad AN, El Hagrasy AS. Characterization and optimization of orodispersible mosapride film formulations. AAPS PharmSciTech [Internet]. 2011;12(4):1384–92. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3225544&tool=pmcentrez&rendertype=abstract CrossRefGoogle Scholar
- 7.Sakashita M, Yamaguchi T, Miyazaki H, Sekine Y, Nomiyama T, Tanaka S, et al. Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Arzneimittelforschung. 1993;43(8):867–72.Google Scholar
- 8.Sayed OM, Ali AA, El-Nabarawi MA, Bary AA. Bioequivalence study of buccal formulations of two prokinetic agents versus the conventional oral tablets. Int J Drug Deliv. 2013;5(3):257–63.Google Scholar
- 11.Ibrahim WM, AlOmrani AH, Yassin AEB. Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeability. Int J Nanomedicine [Internet]. 2014;9:129–44. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3872145&tool=pmcentrez&rendertype=abstract Google Scholar
- 14.Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomedicine. 2011;6:363–71.Google Scholar
- 17.Li B, Ge Z-Q. Nanostructured lipid carriers improve skin permeation and chemical stability of idebenone. AAPS PharmSciTech [Internet]. 2012 [cited 2018 mar 16];13(1):276–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22234598.
- 19.Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomedicine. 2011;6:683–92.Google Scholar
- 21.Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M, Hernandez RM. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surfaces B Biointerfaces [Internet]. 2015;134:304–13. Available from. https://doi.org/10.1016/j.colsurfb.2015.06.054.CrossRefGoogle Scholar
- 25.Morsi NM, Ghada A, Abdelbary MAA. Article|Preparation and physicochemical characterization of mosapride citrate pharmacosomes|Inventi Journals Pvt.Ltd. Inven Impact NDDS, 2014(4)233–237 [Internet]. 2014;4:233–7. Available from: http://inventi.in/journal/article/impact/2/11197/ndds/pi
- 27.Sharma D, Maheshwari D, Philip G, Rana R, Bhatia S, Singh M, et al. Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using Box-Behnken design:in vitro and in vivo evaluation. Biomed Res Int. 2014;2014:1–14.Google Scholar
- 30.Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm [Internet]. 1983 May [cited 2017 Jul 27];15(1):25–35. Available from: http://linkinghub.elsevier.com/retrieve/pii/0378517383900649 CrossRefGoogle Scholar
- 31.Hassan EE, Gallo JM. A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength. Vol. 7, Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists. 1990. p. 491–5.Google Scholar
- 36.Soliman SM, NS Abdel Malak, ON El-Gazayerly Nabaweya A. Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: Optimization using 23 factorial design and in vivo evaluation in rabbits. 2015.Google Scholar
- 37.Malak NSA. Formulation of coated polymer reinforced gellan gum beads of Tizanidine HCL using fractional factorial design. Int J Pharm Pharm Sci. 2012;4(SUPPL. 5):369–79.Google Scholar
- 40.Üstündağ Okur N, Apaydın Ş, Karabay Yavaşoğlu NÜ, Yavaşoğlu A, Karasulu HY. Evaluation of skin permeation and anti-inflammatory and analgesic effects of new naproxen microemulsion formulations. Int J Pharm [Internet]. 2011 [cited 2018 Mar 7];416(1):136–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21723930.
- 41.Center for Drug Evaluation and Research. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. US Dep Heal Hum Serv [Internet]. 2005 [cited 2018 Jun 9];(July):1–27. Available from: http://www.fda.gov/cder/guidance/index.htm
- 44.Mitchell CF, Malone ED, Sage AM, Niksich K. Evaluation of gastrointestinal activity patterns in healthy horses using B mode and Doppler ultrasonography. Can Vet J = La Rev Vet Can [Internet]. 2005 [cited 2018 mar 17];46(2):134–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15825515.
- 45.Zhou D, Qiu Y. Dissolution and in vitro - in vivo correlation. J Valid Technol. 2010;Winter:57–70.Google Scholar
- 46.Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm [Internet]. 2011;415(1–2):232–43. Available from. https://doi.org/10.1016/j.ijpharm.2011.05.044.CrossRefGoogle Scholar
- 47.Hedaya MA. Basic pharmacokinetics, Second Edition. Pharm Press www.pharmpress.com. 2012;105–26.
- 50.Sanad RA, Malak NSA, El-Bayoomy TS, Badawi AA. Preparation and characterization of oxybenzone-loaded solid lipid nanoparticles (SLNs) with enhanced safety and sunscreening efficacy: SPF and UVA-PF. Drug Discov Ther. 2010;4(6):472–83.Google Scholar
- 51.RC Rowe, Paul J, Sheskey, SCO. Handbook of pharmaceutical excipients 5th edition.pdf. Raymond C Rowe, Paul J Sheskey SCO, editor. London. Chicago: Pharmaceutical Press and American Pharmacists Association 2006; 2006.Google Scholar
- 54.Khalil RM, El-bary AA, Kassem MA, Ghorab MM, Basha M. Influence of formulation parameters on the physicochemical properties of meloxicam-loaded solid lipid nanoparticles. Egyptian Pharm J 2013;63–72.Google Scholar
- 55.Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine Nanotechnology Biol Med [Internet]. 2009;5(2):184–91. Available from. https://doi.org/10.1016/j.nano.2008.08.003.CrossRefGoogle Scholar
- 57.Mitrea E, Lacatusu I, Badea N, Ott C, Oprea O, Meghea A. New approach to prepare willow bark extract–lipid based nanosystems with enhanced antioxidant activity. J Nanosci Nanotechnol [Internet]. 2015;15(6):4080–9. Available from: http://openurl.ingenta.com/content/xref?genre=article&issn=1533-4880&volume=15&issue=6&spage=4080 CrossRefGoogle Scholar
- 63.Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm [Internet]. 2011 May [cited 2017 Sep 11];409(1–2):260–8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0378517311001864 CrossRefGoogle Scholar
- 64.Mohammadi M, Pezeshki A, Mesgari Abbasi M, Ghanbarzadeh B, Hamishehkar H. Vitamin D3-loaded nanostructured lipid carriers as a potential approach for fortifying food beverages; in vitro and in vivo evaluation. Adv Pharm Bull [Internet]. 2017 [cited 2017 Sep 11];7(1):61–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28507938.CrossRefGoogle Scholar
- 67.Patel NR, Patel DA, Bharadia PD, Pandya V, Modi D. Microsphere as a novel drug delivery. Int J Pharm Life Sci. 2011;2(8):992–7.Google Scholar
- 68.Chronopoulou L, Massimi M, Giardi MF, Cametti C, Devirgiliis LC, Dentini M, et al. Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures. Colloids Surfaces B Biointerfaces [Internet]. 2013;103:310–7. Available from. https://doi.org/10.1016/j.colsurfb.2012.10.063.CrossRefGoogle Scholar
- 70.Shete AS, Yadav A V, Murthy SM. Chitosan and chitosan chlorhydrate based various approaches for enhancement of dissolution rate of carvedilol. Daru [Internet]. 2012 [cited 2018 May 25];20(1):93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23351907.
- 73.Seyfoddin A., Sherwin T., Patel D., McGhee C., Rupenthal TJ and Taylor JA, Al-Kassas R. Ex vivo and in vivo evaluation of chitosan coated nanostructured lipid carriers for ocular delivery of acyclovir. 2016. p. 13.Google Scholar
- 77.Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery systems. BioImpacts. 2012;2(4):175–87.Google Scholar
- 82.Ebrahimi HA, Javadzadeh Y, Hamidi M, Jalali MB. Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles. Daru [Internet]. 2015;23(1):46. Available from. https://doi.org/10.1186/s40199-015-0128-3.CrossRefGoogle Scholar
- 84.General Chapters_ _401_ Fats and fixed oils.pdf [Internet]. [cited 2018 Jul 30]. Available from: http://www.pharmacopeia.cn/v29240/usp29nf24s0_c401.html
- 86.Jambhekar SS, Breen PJ. Basic pharmacokinetics. Taylor & Francis/CRC Press; 2009.p. 425Google Scholar
- 87.Hernandez RM, Gascon AR, Calvo MB, Caramella C, Conte U, Dominguez-Gil A, et al. Influence of route of administration and dosage form in the pharmacokinetics and bioavailability of salbutamol. Eur J Drug Metab Pharmacokinet [Internet]. 1997;22(2):145–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9248783 CrossRefGoogle Scholar
- 88.Cheng C, Wu PC, Lee HY, Hsu KY. Development and validation of an in vitroein vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations. J Food Drug Anal [Internet]. 2014;22(2):257–63. Available from. https://doi.org/10.1016/j.jfda.2013.09.016.CrossRefGoogle Scholar